Hormonal & Signaling Research
CJC-1295 + IPAMORELIN (NO DAC)
Select all options to continue.
Description
🧬 CJC-1295 (No DAC) + Ipamorelin
Dual Peptide Blend | ≥99% HPLC Verified | Research Grade
Â
CJC-1295 No DAC 5mg + Ipamorelin 5mg (10mg Total) & (20mg Total)
This dual-peptide research blend combines CJC-1295 (No DAC) and Ipamorelin. The combination is widely examined in laboratory settings for its interaction with growth hormone–related signaling pathways and receptor synergy models.
CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog designed without the Drug Affinity Complex (DAC), resulting in a shorter functional activity profile suitable for pulsatile signaling research.
Ipamorelin is a selective growth hormone secretagogue studied for its interaction with the ghrelin receptor (GHS-R1a) in controlled experimental models.
SPEC manufactures this blend under strict laboratory conditions with analytical verification to ensure purity, identity, and batch consistency.
Â
Why Researchers Choose SPEC CJC-1295 + Ipamorelin
- 5mg CJC-1295 (No DAC) + 5mg Ipamorelin
- 10mg total peptide content per vial
- ≥99% purity (HPLC verified per component)
- Mass spectrometry sequence confirmation
- Controlled lyophilization process
- Batch-level analytical verification
- Manufactured exclusively for laboratory research use
Â
Mechanism of Action (Research Context)
CJC-1295 (No DAC)
Studied as a GHRH analog interacting with growth hormone–releasing hormone receptors in experimental endocrine pathway models. The absence of DAC allows for shorter-duration receptor activation patterns in laboratory research.
Ipamorelin
Investigated as a selective ghrelin receptor (GHS-R1a) agonist influencing growth hormone–related signaling cascades in controlled studies.
Combined Research Interest
The combination is commonly examined in:
- Growth hormone axis pathway research
- Receptor synergy and dual-pathway studies
- Pulsatile endocrine signaling models
- Peptide interaction research
- Experimental hormone regulation analysis
Â
 Quality & Analytical Verification
Each SPEC batch undergoes:
- High-Performance Liquid Chromatography (HPLC) purity testing
- Mass spectrometry identity confirmation
- Controlled lyophilization under monitored conditions
- Visual inspection for particulate consistency
Our specification-driven release process ensures reproducibility and consistency across research batches.
Â
âš Research Use Disclaimer
This product is intended strictly for laboratory research use only. Not for human consumption. Not for medical, diagnostic, or therapeutic use. Purchaser assumes responsibility for compliance with applicable regulations.
Additional Information
- Available Total Quantity (10mg):
- CJC-1295 (No DAC) – 5mg Ipamorelin – 5mg
- Available Total Quantity (20mg):
- CJC-1295 (No DAC) – 10mg Ipamorelin – 10mg
- Purity
- ≥99% (HPLC per peptide component)
- Appearance
- White to off-white lyophilized powder
- Storage Conditions
- Store at -20°C for long-term stability
- Grade
- Research use only




